請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16270
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄧哲明,潘秀玲 | |
dc.contributor.author | Hui-Hsuan Huang | en |
dc.contributor.author | 黃惠暄 | zh_TW |
dc.date.accessioned | 2021-06-07T18:07:32Z | - |
dc.date.copyright | 2012-09-18 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-07-22 | |
dc.identifier.citation | Arce F, Gatjens-Boniche O, Vargas E, Valverde B and Diaz C (2005) Apoptotic events induced by naturally occurring retinoids ATRA and 13-cis retinoic acid on human hepatoma cell lines Hep3B and HepG2. Cancer Lett 229: 271-281.
Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR and Byrd JC (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8–mediated apoptosis and down-regulation of c-FLIP protein. Blood 102: 652-658. Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Häcker S, Vellanki S, Lausen J, Debatin K-M and Fulda S (2012) Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene (in press) Berger SL, Kouzarides T, Shiekhattar R and Shilatifard A (2009) An operational definition of epigenetics. Genes Dev 23: 781-783. Bolden JE, Peart MJ and Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784. Bruix J and Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236. Bruix J and Sherman M (2011) Management of hepatocellular carcinoma: An update. Hepatology 53: 1020-1022. Bullani R, Huard B, Viard-Leveugle I, Byers H, Irmler M, Saurat J-H, Tschopp J and French LE (2001) Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol 117: 360-364. Chan SL and Yeo W (2012) Targeted therapy of hepatocellular carcinoma: Present and future. J Gastroenterol Hepatol 27: 862-872. Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I and Stärkel P (2010) Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer 9: 256. Chou TC and Talalayi P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55. Du X, Bao G, He X, Zhao H, Yu F, Qiao Q, Lu J and Ma Q (2009) Expression and biological significance of c-FLIP in human hepatocellular carcinomas. J Exp Clin Cancer Res 28: 24. El-Serag HB, Marrero JA, Rudolph L and Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134: 1752-1763. Füllgrabe J, Hajji N and Joseph B (2010) Cracking the death code: apoptosis-related histone modifications. Cell Death Differ 17: 1238-1243. Füllgrabe J, Kavanagh E and Joseph B (2011) Histone onco-modifications. Oncogene 30: 3391-3403. Farazi PA and DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687. Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5: 876-885. Fink SL and Cookson BT (2007) Pyroptosis and host cell death responses during Salmonella infection. Cell Microbiol 9: 2562-2570. Forner A, Llovet JM and Bruix J (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH and Walczak H (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11: S86-S96. Ge R, Wang Z, Zeng Q, Xu X and Olumi AF (2011) F-box protein 10, an NF-kappaB- dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway. Cell Death Differ 18: 1184-1195. Glozak MA, Sengupta N, Zhang X and Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23. Hanahan D and Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674. Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH and Evers BM (2001) Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 130: 265-272. Hotchkiss RS, Strasser A, McDunn JE and Swanson PE (2009) Mechanisms of disease cell death. N Engl J Med 361: 1570-1583. Hutchinson L (2011) Targeted therapies: doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma. Nature Reviews Clinical Oncology 8: 61. Igney FH and Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner Vr, Bodmer J-C, Schröter M, Burns K, Mattmann C, Rimoldi D, French LE and Tschopp J (1997) Inhibition of deathreceptor signals by cellular FLIP. Nature 388: 190-195. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. Jin Z and El-Deiry WS (2005) Overview of cell death signaling pathways. Cancer Biol Ther 4: 139-163. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, Strasser A and Kaufmann T (2009) XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460: 1035-1039. Kerr E, Holohan C, McLaughlin KM, Majkut J, Dolan S, Redmond K, Riley J, McLaughlin K, Stasik I, Crudden M, Van Schaeybroeck S, Fenning C, O'Connor R, Kiely P, Sgobba M, Haigh D, Johnston PG and Longley DB (2012) Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ (in press) Khan O and La Thangue NB (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94. Krueger A, Baumann S, Krammer PH and Kirchhoff S (2001) FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21: 8247-8254. Li J and Yuan J (2008) Caspases in apoptosis and beyond. Oncogene 27: 6194-6206. Llovet JM and Bruix J (2008a) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J (2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL and Dienstag JL (2010) Des-γ-carboxy prothrombin and α-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138: 493-502. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL and Chen CS (2007) Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 46: 1119-1130. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly W (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202. Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA and Bates GP (2011) SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS One 6: e27746. Ocker M and Schneider-Stock R (2007) Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 39: 1367-1374. Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Fujikawa K, Murata K and Nakano T (2003) Cellular FLICE/ caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83: 1033-1043. Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M, Lauer UM and Bitzer M (2006) HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 43: 425-434. Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Seiden I, Keen SL, Tawa P, Xanthoudakis S, Nasir J, Martindale D, Koop BF, Peterson EP, Thornberry NA, Huang J, MacPherson DP, Black SC, Hornung F, Lenardo MJ, Hayden MR, Roy S and Nicholson DW (1998) Cell death attenuation by ’Usurpin’, a mammalian DED-caspase homologue that precludes caspase 8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ 5: 271–288. Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M and Maehara Y (2007) Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 72: 69-74. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ and Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 98: 10833-10838. Ryu BK, Lee MG, Chi SG, Kim YW and Park JH (2001) Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 194: 15-19. Safa AR and Pollok KE (2011) Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers 3: 1639-1671. Savill J and Fadok V (2000) Corpse clearance defines the meaning of cell death. Nature 407(12): 784-788. Scaffidi C, Schmitz I, Krammer PH and Peter ME (1999) The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 274: 1541–1548. Schmitz I, Kirchhoff S and Krammer PH (2000) Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 32: 1123-1136. Shi Y (2002) Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9: 459–470. Spiegel S, Milstien S and Grant S (2012) Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31: 537-551. Villanueva A and Llovet JM (2011) Targeted therapies for hepatocellular carcinoma. Gastroenterology 140: 1410-1426. Vucic D, Dixit VM and Wertz IE (2011) Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 12: 439-452. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen TY, Huang YJ and Lu SN (2008) The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-survival analysis of 3892 patients. Eur J Cancer 44: 1000-1006. Whittaker S, Marais R and Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM, Johnston PG and Longley DB (2007) c-FLIP: A key regulator of colorectal cancer cell death. Cancer Res 67: 5754-5762. Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez Saiz F, Gronda M, Eberhard Y, MacLean N, Ketela T, Reed JC, Moffat J, Minden MD, Batey RA and Schimmer AD (2010) Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther 9: 246-256. Xu WS, Parmigiani RB and Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552. Yerbes R and Lopez-Rivas A (2012) Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL. Invest New Drugs 30: 541-547. Youle RJ and Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59. Zhang L and Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237. Zhang XD, Gillespie SK, Borrow JM and Hersey P. (2004) The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 3: 425–435. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET and Yu Q (2005) Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A 102: 16090-16095. Zhu AX (2006) Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11: 790–800. Zhu WG, Lakshmanan RR, Beal MD and Otterson GA (2001) DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61: 1327–1333. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16270 | - |
dc.description.abstract | 肝癌是造成國人癌症致死率居高不下的主要原因之一,雖然多激酶抑制劑 (multikinase inhibitor) sorafenib能有效地增加肝細胞癌病患的存活期,但目前還需要更多能有效治療此癌症的藥物。目前HDAC抑制劑被認為是具有潛力的抗癌藥物,其能促進細胞凋亡並使細胞週期停滯,因此本篇論文之目的為評估一個新合成的HDAC抑制劑 MPT0G009在肝細胞癌的抗癌效果。實驗結果顯示,MPT0G009作用在人類肝細胞癌細胞比起已核准上市的HDAC抑制劑 SAHA,有更強的細胞生長抑制作用、細胞毒殺作用和HDAC抑制作用。並透過fluorogenic HDAC assay kit得知MPT0G009為一個pan-HDAC抑制劑;我們發現MPT0G009在人類肝細胞癌Hep3B細胞中會增加組蛋白H3和α-tubulin乙醯化並且增加p21WAF1/CIP1蛋白表現,此現象證實MPT0G009在Hep3B細胞內的確具有HDAC抑制作用並引起下游的反應。進一步實驗顯示,MPT0G009會調控Hep3B細胞凋亡之訊息傳遞,包括其會增加subG1期的Hep3B細胞以及造成Hep3B細胞的粒線體膜電位下降,並且活化其caspase cascade、增加proapoptotic蛋白 Bim、減少 Bid proform以及減少antiapoptotic蛋白 Bcl-2、Bcl-xL和FLIPS/L,我們也在Hep3B細胞中,證實MPT0G009所引起的細胞凋亡與其抑制HDAC的作用有密不可分的關係。另外,我們還發現MPT0G009對Hep3B細胞短時間作用下,會透過加速FLIPS/L蛋白被分解和減少其轉錄來降低FLIPS/L蛋白表現。因此,MPT0G009合併使用TRAIL或TNF-α均能產生協同作用來抑制人類肝細胞癌細胞的生長,證實MPT0G009會使TRAIL-resistant的人類肝細胞癌細胞,如Hep3B和Huh7細胞對TRAIL轉而敏感化。最後,在腫瘤移植的動物模式中也看到,MPT0G009能有效地抑制Hep3B異種移植腫瘤的生長,MPT0G009會增加α-tubulin和組蛋白H3乙醯化、活化caspase 9、增加PARP cleavage的現象以及減少FLIPS/L,這些作用與in vitro結果相符。總結來說,新穎的HDAC抑制劑 MPT0G009在人類肝細胞癌細胞中,能有效地抑制HDAC並促進外生性和內生性的細胞凋亡路徑,迄今尚未有HDAC抑制劑被核准用來治療肝細胞癌,因此MPT0G009可望成為新一代的肝細胞癌治療藥物。 | zh_TW |
dc.description.abstract | Hepatocellular carcinoma (HCC) is one of the common cause of cancer-related death in Taiwan. Although the multikinase inhibitor, sorafenib, significantly increases overall survival of HCC patients, more effective anti-cancer therapies for the treatment of HCC are needed. In addition, histone deacetylase (HDAC) inhibitors serve as promising anti-cancer drugs because of their ability to induce cell growth arrest and apoptosis. The purpose of this study is to evaluate the anti-cancer effects of a novel synthetic HDAC inhibitor, MPT0G009, in HCC. Our data showed that the growth-inhibitory, cytotoxicity and HDAC-inhibitory effects of MPT0G009 were more potent than suberoylanilide hydroxamic acid (SAHA), a FDA approved HDAC inhibitor, in HCC cells. By fluorogenic HDAC assay kit, we suggested that MPT0G009 is a pan-HDAC inhibitor. Moreover, MPT0G009 increased histone H3 acetylation, α-tubulin acetylation and p21WAF1/CIP1 protein, which indicated that MPT0G009 exhibits HDAC inhibitory activity in hepatocellular carcinoma Hep3B cells. Furthermore, MPT0G009- induced apoptosis of Hep3B cells was characterized by an increase in apoptotic (sub-G1) population of Hep3B cells, a loss of mitochondrial membrane potential, the activation of caspase cascade, an increase in proapoptotic protein Bim , a decrease in Bid proform and antiapoptotic proteins, such as Bcl-2, Bcl-xL and FLIPS/L. We also proved that MPT0G009-induced apoptosis was closely related to its activity of HDAC inhibition in Hep3B cells. Interestingly, we observed that the short-term treatment of Hep3B cells with MPT0G009 downregulated FLICE- inhibitory protein (FLIP) through proteasome-mediated degradation and transcriptional suppression. In addition, we observed the synergism of growth inhibition between MPT0G009 and TRAIL/TNF-α in HCC cells. It is proved that MPT0G009 sensitized Hep3B and Huh7 cells to TRAIL. Most importantly, MPT0G009 exhibited the tumor-inhibitory activity in Hep3B mouse xenograft models. MPT0G009 increased α-tubulin acetylation, increased histone H3 acetylation, activated caspase 9, increased PARP cleavage and decreased FLIPS/L in vivo. These results were consistent with in vitro results. In conclusion, MPT0G009, a new HDAC inhibitor, potently inhibits HDAC and triggers both the extrinsic and intrinsic apoptotic pathways in HCC cells. So far, there is no HDAC inhibitor approved for HCC. Thus, MPT0G009 may represent a new candidate for the treatment of HCC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T18:07:32Z (GMT). No. of bitstreams: 1 ntu-101-R99443019-1.pdf: 3157113 bytes, checksum: b7ce79ae7d14948e91370809259eb880 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 口試委員會審定書…………………………I
誌謝…………………………………………II 縮寫表………………………………………III 中文摘要……………………………………IV 英文摘要……………………………………V 第一章 研究動機與目的……………………1 第二章 文獻回顧……………………………2 第三章 實驗材料與方法 第一節 實驗材料……………………………25 第一節 實驗方法……………………………27 第四章 實驗結果……………………………36 第五章 討論…………………………………41 第六章 結論與展望…………………………47 參考文獻 ……………………………………62 | |
dc.language.iso | zh-TW | |
dc.title | 探討新組蛋白去乙醯酶抑制劑MPT0G009誘發細胞凋亡與合併TRAIL呈現協同作用於人類肝癌細胞之體外和體內的作用機轉 | zh_TW |
dc.title | Novel synthetic histone deacetylase inhibitor MPT0G009 induces cell apoptosis and displays synergistic anticancer activity with TRAIL against human hepatocellular carcinoma in vitro and in vivo. | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃德富,顏茂雄,楊春茂 | |
dc.subject.keyword | 肝癌,組蛋白去乙醯酶,細胞凋亡, | zh_TW |
dc.subject.keyword | hepatocellular carcinoma,histone deacetylase,apoptosis, | en |
dc.relation.page | 68 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2012-07-23 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 3.08 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。